Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06535412
PHASE1/PHASE2
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of active SLE.
Official title: A Multi-center, Randomized, Double-blind, Placebo Control Phase 1b/II Study to Evaluate the Safety and Efficacy of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
218
Start Date
2024-10-10
Completion Date
2026-06-10
Last Updated
2024-08-02
Healthy Volunteers
No
Conditions
Interventions
DRUG
IMC-002 + SOC
intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg
DRUG
Placebo + SOC
intravenous injection of Placebo